Insider · CIK 0001353128
Barbara Gayle Duncan
director
Files at HALO (HALOZYME THERAPEUTICS, INC.), AVIR (Atea Pharmaceuticals, Inc.), OVID (Ovid Therapeutics Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Common Stock | +29,600 | $0.00 | $0 | 62,750 | Jun 24, 2025 |
| Jun 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +29,600 | $0.00 | $0 | 29,600 | Jun 24, 2025 |
| Jun 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +41,200 | $0.00 | $0 | 41,200 | Jun 24, 2025 |
| Jun 20, 2025 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -29,600 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Feb 20, 2025 | OVID Ovid Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 18, 2025 |
| May 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | AGrant or award Common Stock | +4,165 | $0.00 | $0 | 19,919 | May 2, 2025 |
| May 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | AGrant or award Option to Purchase Common Stockderivative | +5,750 | $0.00 | $0 | 5,750 | May 2, 2025 |
| Dec 12, 2024 | OVID Ovid Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Dec 16, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.